Flu Jab 2026: Updated Vaccine Rolls Out as NHS Fears Early Super-K Surge
The 2026-2027 flu vaccination campaign is officially underway in England, with millions of children and pregnant women now eligible to receive the jab. This year's vaccine has been reformulated to better protect against the Super-K strain that drove last winter's unusually early and severe flu season. The first doses are being administered from Tuesday, September 1, to schoolchildren and pregnant women—groups that are both highly susceptible to catching and spreading the virus.
The NHS is rolling out the vaccine earlier than usual for these priority groups, with other eligible categories, including adults aged 65 and over, set to receive invitations from October. The updated vaccine comes after last winter's flu season began more than a month earlier than normal, fueled by a mutated variant that put significant strain on hospitals already recovering from an unprecedented summer. With health services still under pressure, NHS officials are urging everyone who qualifies for a free flu jab to come forward as soon as they are offered it.
Who Can Get the Vaccine and When?
Children aged two and three, as well as school-aged children from Reception to Year 11, can receive the vaccine—administered as a nasal spray—through their GP or school health programmes. Pregnant women can also get the jab immediately, either at GP surgeries, pharmacies, or maternity services. Other eligible groups, including those aged 65 and over, people with certain long-term health conditions, care home residents, and carers, will start receiving their vaccinations from October 1. This staggered approach aims to protect the most vulnerable and reduce transmission early in the season.
The NHS is also offering the vaccine through high street pharmacies, with many allowing online bookings through the NHS App. For those not eligible for a free jab, private options are available for around £10 to £20. The vaccine cannot cause flu, but it helps the body build immunity before the virus begins circulating widely. The last winter's NHS data shows that nearly 19 million people were vaccinated, helping to avert an estimated 104,000 hospital admissions—a figure health officials are keen to repeat or improve upon.
Why This Year's Vaccine Is Different
The key change this year is the inclusion of a component targeting the subclade K strain of influenza, commonly referred to as "Super-K." While not a medical term, the nickname reflects the public's and clinicians' experience with a variant that spread quickly and caused severe illness, particularly among younger age groups. Influenza viruses mutate constantly, and each year's vaccine is updated to match the strains predicted to circulate. The Super-K strain emerged unexpectedly last autumn, catching many by surprise and leading to a significant rise in hospitalisations.
Public health experts are closely monitoring flu activity in the southern hemisphere, where the season peaks between July and August, to predict what might happen in the UK. This year, Australia has reported fewer cases than last season, but New Zealand has experienced high numbers. This mixed picture has led NHS officials to adopt a cautious approach. Dr Amanda Doyle from NHS England stressed that "last year's flu season came early and was made worse by a new variant," adding that "with services already under significant pressure, it is vital that everyone offered the vaccine comes forward."
A Shift Towards mRNA Technology
Beyond the immediate rollout, the 2026 flu season marks a significant shift in vaccine technology. For the first time, an mRNA-based flu vaccine has been approved and is being introduced in the United States. Developed by Moderna and approved for people aged 50 and over, the vaccine—mFLUSIVA—has been shown to be 25% more effective than traditional shots in that age group. This approval follows a period of regulatory uncertainty, but it represents a major step forward in the fight against seasonal influenza.
The success of mRNA vaccines against COVID-19 has accelerated research into their use for other respiratory viruses. GSK is also advancing its own mRNA flu vaccine, with Phase 3 trials set to begin this month. The company reports that its candidate, which targets both haemagglutinin and neuraminidase antigens, produced higher immune responses than existing vaccines in a mid-stage study. If successful, this could lead to more effective and longer-lasting protection against flu, particularly for older adults who typically respond poorly to conventional vaccines.
Looking Ahead: A Winter of Uncertainty
Despite the advances, experts caution that flu remains unpredictable. The effectiveness of last year's vaccine was only about 36%, and this year's updated shot is designed to better match the circulating strains, but there are no guarantees. With vaccination rates for respiratory viruses declining in some populations, health officials are stressing the importance of community immunity. The early rollout to children is particularly crucial, as they are efficient spreaders of flu to more vulnerable relatives.
As the NHS prepares for another demanding winter, the hope is that the combination of an updated vaccine, earlier deployment, and the eventual introduction of mRNA options will soften the impact. For now, the message is clear: if you're eligible, get your flu jab as soon as possible. The vaccine is safe, effective, and available now.
For those planning their autumn activities, the flu jab is just one of many health considerations. And while the sports world gears up for events like the USA's quest for a fifth straight FIBA Women's World Cup, health officials are focused on ensuring that the nation is protected against the seasonal bugs that can derail everyday life.
With the vaccine now rolling out, the next few weeks will be critical in determining whether the UK can avoid a repeat of last winter's early and severe flu season. Health experts are watching the data closely, ready to adapt if needed.
For more information, visit the NHS website or speak to your GP or local pharmacist about booking your flu vaccination.
Comments